Convergent Therapeutics, an oncology startup targeting prostate cancer, announced on Wednesday it raised $90 million in Series A funding. The round was led by OrbiMed and RA Capital Management, with additional participation from Invus.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,